

LETTER TO THE EDITOR

Open Access

A new method for maturity-dependent fractionation of neutrophil progenitors applicable for the study of myelodysplastic syndromes

Huiyuan Hu^{1,2}, Yayoi Shikama^{1*}, Tsutomu Shichishima^{3,4}, Kazuhiko Ikeda³, Kazuko Akutsu^{3,5}, Tomoyuki Ono¹, Hideo Kimura⁶, Kazuei Ogawa³, Hideyoshi Noji³, Yasuchika Takeishi³ and Junko Kimura¹

Abstract

We applied our new method, maturity-dependent fractionation of bone marrow-derived neutrophil progenitors, to a study of gene expression profiles during granulopoiesis in myelodysplastic syndromes. CD34⁺ cells with low density [F1], CD11b⁻/CD16⁻ [F2], CD11b⁺/CD16⁻ [F3] and CD11b⁺/CD16^{low} [F4] with intermediate density, CD11b⁺/CD16^{int} [F5] and CD11b⁺/CD16^{high} [F6] with high density were isolated from six patients. Although AML1 and C/EBP-ε mRNA peaked at F1 and F4, respectively, in healthy individuals, C/EBP-ε was maximized at F2/F3 in all patients, two of whom showed simultaneous peaks of AML1 at F2. Thus, this fractionation is useful to detect mistimed induction of granulopoiesis-regulating genes in myelodysplastic syndromes.

Keywords: Myelodysplastic syndromes, AML1, C/EBP-ε, Granulopoiesis, Fractionation, Gene expression profile

To the editor

Myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cells characterized by cytopenia with dysplastic phenotypes of myeloid cells [1], which have been thought to result from defective differentiation [2]. However, the molecular basis of impaired differentiation is largely unclear. Since *in vivo* gene expression profiles during granulopoiesis in MDS have not been studied because of the lack of an appropriate method to fractionate progenitors, we applied our newly established method that separates bone marrow (BM)-derived neutrophil progenitors into six sequential maturation stages [3] for BM specimens of six low-risk MDS patients (Table 1). All volunteers provided a written form of informed consent in accordance with the institutional Human Research Committee and Helsinki Declaration.

Heparinized BM blood was divided into low (<1.065 g/mL), intermediate (between 1.065 g/mL and 1.080 g/mL), and high density (>1.080 g/mL) populations. The

overall recovery rate (73.7 ± 12.4%) did not differ from the results of healthy BM [3]. Non-neutrophil lineages expressing CD2, CD3, CD14, CD19, CD56, CD61, glycophorin-A, or CD49d were eliminated, and the remaining cells were subjected to immunostaining for fluorescence activated cell sorting of CD34⁺ cells with low density [F1], CD11b⁻/CD16⁻ [F2], CD11b⁺/CD16⁻ [F3], and CD11b⁺/CD16^{low} [F4] with intermediate density, as well as CD11b⁺/CD16^{int} [F5] and CD11b⁺/CD16^{high} [F6] with high density. The six fractions derived from MDS patients well correlated with morphological maturation of neutrophil progenitors (Table 2), as previously shown using healthy BM.

The BM-derived fractions and a peripheral blood-derived neutrophil fraction [F7] were subjected to quantification of mRNA of acute myeloid leukemia 1 (AML1), CCAAT-enhancer-binding protein-epsilon (C/EBP-ε), and ecotropic viral integration site 1 (EV11) as previously described [3]. As shown in Figure 1, four out of the six patients showed peak expressions of AML1 mRNA at F1 followed by a gradual decrease as previously shown in healthy BM [3]. However, two patients, refractory cytopenia with multilineage dysplasia (RCMD)1 and RCMD2,

* Correspondence: yayois@fmu.ac.jp

¹Department of Pharmacology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Japan
Full list of author information is available at the end of the article

Table 1 Clinical and hematological findings and treatment in six patients with MDS


Diagnosis	Age/sex	WBC ($\times 10^9/L$)	ANC ($\times 10^9/L$)	Hb (g/dL)	PLT ($\times 10^9/L$)	BM NCC ($\times 10^9/L$)	Karyotypes	Therapy
RCUD	74/M	4.5	3.5	8.4	206	143	46,XY	None
RCMD 1	66/M	2.4	1.7	9.2	46	37	46,XY	None
RCMD 2	79/F	3.5	2.0	10.3	6	50	46,XX	RBC and platelet transfusion
RCMD 3	73/M	2.8	1.4	10.3	79	207	46,XY,del(20)(q11)	None
RCMD 4	26/F	4.0	0.9	11.2	50	35	46,XX	None
RARS	83/M	4.8	3.4	6.1	336	240	46,XY	None

Abbreviations; WBC white blood cell counts, ANC absolute neutrophil counts, Hb concentration of hemoglobin, PLT platelet counts. BM NCC bone marrow nucleated cell counts, M male, F female, RBC red blood cells, RCUD refractory cytopenia with unilineage dysplasia, RCMD refractory cytopenia with multilineage dysplasia, RARS refractory anemia with ringed sideroblasts.

Table 2 Morphological counts of the cells included in sorted fractions

	MB	PM	MC	MM	SB	SE	Others
F1	69.7 ± 23.7%	29.3 ± 22.8%	0.3 ± 0.3%	0.0 ± 0.0%	0.0 ± 0.0%	0.0 ± 0.0%	0.7 ± 0.6%
F2	0.0 ± 0.0%	47.8 ± 16.1%	55.8 ± 17.1%	0.5 ± 0.4%	0.3 ± 0.4%	0.0 ± 0.0%	2.5 ± 4.8%
F3	0.2 ± 0.4%	0.5 ± 0.5%	80.1 ± 18.0%	11.4 ± 14.7%	1.3 ± 1.9%	0.2 ± 0.5%	5.7 ± 11.4%
F4	0.0 ± 0.0%	0.3 ± 0.8%	70.3 ± 29.0%	24.6 ± 20.6%	4.3 ± 5.9%	0.4 ± 0.7%	0.0 ± 0.0%
F5	0.0 ± 0.0%	0.0 ± 0.0%	17.4 ± 8.3%	29.8 ± 20.1%	49.4 ± 24.3%	7.9 ± 7.2%	1.3 ± 3.0%
F6	0.0 ± 0.0%	0.0 ± 0.0%	1.1 ± 1.5%	7.0 ± 4.9%	57.5 ± 11.5%	34.4 ± 15.7%	0.1 ± 0.2%

The numbers represent mean ± SD. MB; myeloblasts, PM; promyelocytes, MC; myelocytes, MM; metamyelocytes, SB; neutrophils with stab nuclei, SE; neutrophils with segmented nuclei, others: non-neutrophilic lineages including erythroblasts, monocytes, lymphocytes, and eosinophils.



showed maximum AML1 expressions at F2, which were 28- and 1.8-fold higher than those at F1, respectively. The delayed peak of AML1 mRNA was not due to the contamination of myeloblasts (MBs) in F2, since RCMD1- and RCMD2-derived F2 consisted of mostly promyelocytes (PMs) and myelocytes (MCs), with no MBs. The peak expression of C/EBP- ϵ mRNA was detected at F2 in four patients and at F3 in one patient, while the other patient showed two peaks at F2 and F4. In healthy BM, C/EBP- ϵ mRNA was maximally expressed at F4 [3] following the acquisition of cell-surface expression of CD11b. Simultaneous peaks of C/EBP- ϵ and AML1 at F2 in RCMD1 and RCMD2 were obviously abnormal. The remarkable dropdown and absence of EVI1 mRNA at F2 of RCMD1 and RCMD2, respectively, suggested that both AML1 and C/EBP- ϵ mRNA were specifically increased at F2 in these patients.

These aberrant gene inductions were not detectable by analyses of only a hematopoietic stem cell fraction [4,5], or density-based three fractions [6] which includes F2, F3, and F4 in the same fraction with intermediate density. Thus, our newly established method of neutrophil progenitor fractionation is applicable to MDS, and may provide a new insight into understanding the molecular basis of impaired differentiation.

Competing interests

There are no relevant conflicts of interest to disclose for any of the authors.

Authors' contributions

H H performed this research. Y S designed this study, analyzed the data, and wrote the paper. T S collected patients' samples and revised the paper critically. K I and K A performed cell isolation by fluorescence-activated cell sorter. T O took part of density centrifugation and immunostaining. H K, K O, and H N chose appropriate patients and collected the specimens. Y T and J K critically discussed this study and revised the paper. All authors read and approved the final manuscript.

Acknowledgements

We thank Ms. Sanae Sato (Fukushima Medical University, Fukushima, Japan) for her technical assistance. This study was supported by Grants-in-Aid for Fukushima Medical University Research Project (KK19004) to Y. S. and to H. H., Smoking Research Foundation (grant K118003) to J. K., and a Grant-in-Aid for Scientific Research (C) (MO23591400) to Y. S. from Japan Society for the Promotion of Science.

Author details

¹Department of Pharmacology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Japan. ²Department of Pharmaceutical Toxicology, China Medical University School of Pharmaceutical Sciences, Shenyang, China. ³Department of Cardiology and Hematology, Fukushima Medical University, Fukushima, Japan. ⁴Fukushima Research Institute of Environment and Medicine, Futaba, Japan. ⁵Department of Hematology, Iwaki Kyoritsu General Hospital, Iwaki, Japan. ⁶Department of Hematology, Kita Fukushima Medical Center, Date, Japan.

Received: 27 December 2013 Accepted: 6 January 2014

Published: 22 January 2014

References

1. Scott BL, Deeg HJ: Myelodysplastic syndromes. *Annu Rev Med* 2010, **61**:345–358.
2. Li X, Wu L, Ying S, Chang C, He Q, Pu Q: Differentiation and hematopoietic-support of clonal cells in myelodysplastic syndromes. *Leuk Lymphoma* 2007, **48**(7):1353–1371.

3. Hu H, Shikama Y, Shichishima T, Ikeda K, Akutsu K, Ono T, Kimura H, Ogawa K, Noji H, Takeishi Y, *et al*: Maturity-dependent fractionation of neutrophil progenitors: a new method to examine in vivo expression profiles of differentiation-regulating genes. *Exp Hematol* 2012, **40**(8):675–681.
4. Miyazato A, Ueno S, Ohmine K, Ueda M, Yoshida K, Yamashita Y, Kaneko T, Mori M, Kirito K, Toshima M, *et al*: Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. *Blood* 2001, **98**(2):422–427.
5. Sridhar K, Ross DT, Tibshirani R, Butte AJ, Greenberg PL: Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. *Blood* 2009, **114**(23):4847–4858.
6. Bjerregaard MD, Jurlander J, Klausen P, Borregaard N, Cowland JB: The in vivo profile of transcription factors during neutrophil differentiation in human bone marrow. *Blood* 2003, **101**(11):4322–4332.

doi:10.1186/2050-7771-2-2

Cite this article as: Hu *et al*: A new method for maturity-dependent fractionation of neutrophil progenitors applicable for the study of myelodysplastic syndromes. *Biomarker Research* 2014 **2**:2.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

